Most investigations for ALS and other NDDs have centered on where the damage can be observed – in the brain and central nervous system (CNS). To date, they have yielded little success.
We are pioneers of a broader, emerging paradigm shift where mounting evidence suggests NDDs are manifestations of broader systemic biological dysfunction.
Our discoveries of systemic metabolic dysregulation underpin the novel investigational therapeutic we are developing to intercept a root cause of ALS and our novel biomarker-based technology for early and accurate disease detection.
Both our therapeutic candidate and our biomarker technology can be utilized in the monogenic and sporadic ALS setting.
Our deeply experienced team and world-class academic advisory network are enabling us to accelerate our therapeutic and diagnostic advancements for ALS and potentially other NDDs
We’re excited to share our discoveries and progress with the scientific community.
